

# EGM PRESENTATION

5 November 2014




**cordlife** – A Consumer Healthcare Company, listed on the Mainboard of SGX-ST.



Cordlife Singapore, Hong Kong & India are  
**BB Accredited**

[www.cordlife.com](http://www.cordlife.com)  
Singapore | Hong Kong | India  
Indonesia | Philippines

# Diagrammatic Illustration of Transaction





# Key Parties' Interests in CCBC Prior To And Post-transaction



## Shareholdings (%) in CCBC \*

	Latest Publicly Available Information	Partial Dilution (if only Cordlife and Magnum exercise conversion option)	Full Dilution (If KKR, Cordlife and Magnum all exercise conversion option)
<b>Golden Meditech</b>	42.03%	33.86%	27.03%
<b>KKR</b>	-	-	20.17%
<b>Cordlife</b>	10.02%	17.79%	14.20%
<b>Magnum</b>	-	9.72%	7.76%

\* All figures are rounded to the nearest 2 decimal places



# Key Parties' Interests in CCBC if Cordlife did not participate in the acquisition of Convertible Note



## Shareholdings (%) in CCBC

	Latest Publicly Available Information	Partial Dilution (if KKR exercises conversion option)	Full Dilution (If KKR and Magnum exercise conversion option)
<b>Golden Meditech</b>	42.03%	31.99%	27.03%
<b>KKR</b>	-	23.88%	20.17%
<b>Cordlife</b>	10.02%	7.63%	6.44%
<b>Magnum</b>	-	-	15.52%

\* All figures are rounded to the nearest 2 decimal places

# Salient Terms of the CGL Note and Facility

## PROPOSED ACQUISITION OF 7% SENIOR CONVERTIBLE NOTE (“CGL Note”) DUE 2017 ISSUED BY CHINA CORD BLOOD CORPORATION (“CCBC”)

- 7% coupon on US\$2.838
- Expiry date of convertible notes
  - KKR (27 April 2017);
  - Cordlife/Magnum (3 October 2017)
- CGL Note converts into 8,809,020 fully paid CCBC shares, at a conversion price of approximately US\$5.00, based on the purchase price of approximately US\$44 million
- Assuming redemption of CGL Note upon maturity and taking into account only receipt of 7% coupon payment, salvage value at 12% IRR is equivalent to approximately US\$3.80 per share
- Participating shareholder in excess cash dividend, if CCBC ordinary shareholders receive cash dividend in excess of 7% of US\$2.838 or approximately US\$0.1984 per share
- Penalty on default: Principal amount of CGL Note may be redeemed at a price which, inclusive of interest, would yield a 22.5% IRR on outstanding principal to date of payment

## PROPOSED US\$46,500,000 FACILITY TO BE GRANTED TO MAGNUM OPUS INTERNATIONAL HOLDINGS LIMITED (“MAGNUM”)

- Upfront non-refundable fee of approximately US\$1.45 million paid to Cordlife
- Interest is payable at 7% per annum semi-annually for the first 3 years; and at the higher of 4.6% over the Swap Offer Rate or 7% per annum, in the 4<sup>th</sup> and 5<sup>th</sup> years
- Assuming full drawdown, Cordlife’s interest income shall be US\$3,255,000 in each of the first 3 years, US\$2,848,125 in the 4<sup>th</sup> year and US\$1,220,625 in the 5<sup>th</sup> year
- Facility to be repaid in 4 equal instalments, on the dates falling 42, 48, 54 & 60 months after the 1st drawdown date

# Inorganic growth opportunity: China

## Leveraging platform in China for expansion and growth

### Key China milestones



### China Cord Blood Corporation (NYSE: CO US)

- China's largest cord blood banking operator
- Owns 3 out of 7 issued licenses in PRC to operate cord blood banking. Only 1 licensed operator permitted to operate in each licensed region
- Exclusive license to provide cord blood storage services in Beijing, Guangdong and Zhejiang and approximately 24.0% stake in Shandong Cord Blood Bank
- As at 31 March 2014, CCBC has collaborative relationships with 312 major hospitals in Beijing, Guangdong and Zhejiang.

### Acquisition of China Cord Blood Corporation Convertible Note

- Cordlife able to raise its interest in CCBC from 10.0% to approximately 17.8%
- Magnum (sole shareholder is Mr Yuen Kam, Chairman of CCBC, and management of CCBC) also acquired an equal amount of convertible note in dollar terms which is funded through a facility agreement between Cordlife and Magnum
- Steady source of income from recurring annual coupon payments of US\$1.75 million

# QUESTIONS?

**cordlife**   
one chance, one choice.



**cordlife** – A Consumer Healthcare Company, listed on the Mainboard of SGX-ST.



Cordlife Singapore, Hong Kong & India are  
**BB Accredited**

[www.cordlife.com](http://www.cordlife.com)  
Singapore | Hong Kong | India  
Indonesia | Philippines